The Potential Cost-Effectiveness of a Cell-Based Bioelectronic Implantable Device Delivering Interferon-β1a Therapy Versus Injectable Interferon-β1a Treatment in Relapsing–Remitting Multiple Sclerosis

BACKGROUND: Current first-line disease-modifying therapies (DMT) for multiple sclerosis (MS) patients are injectable or oral treatments. The Optogenerapy consortium is developing a novel bioelectronic cell-based implant for controlled release of beta-interferon (IFNβ1a) protein into the body. The cu...

Descripción completa

Detalles Bibliográficos
Autores principales: Visser, Laurenske A., Folcher, Marc, Delgado Simao, Claudia, Gutierrez Arechederra, Biotza, Escudero, Encarna, Uyl-de Groot, Carin A., Redekop, William Ken
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8739553/
https://www.ncbi.nlm.nih.gov/pubmed/34480325
http://dx.doi.org/10.1007/s40273-021-01081-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8739553/
https://www.ncbi.nlm.nih.gov/pubmed/34480325
http://dx.doi.org/10.1007/s40273-021-01081-y

Ejemplares similares